PALM SPRINGS, Calif., Sept. 10, 2025 /PRNewswire/ — The VIVA Foundation will once again showcase the most influential new data in vascular medicine on a global stage. From Saturday, November 1, through Tuesday, November 4, results from 23 clinical trials will be presented during The VEINS and VIVA conferences at Wynn Las Vegas.
For 23 years, VIVA (Vascular InterVentional Advances) has set the benchmark for premier education and clinical excellence in peripheral vascular disease. Known for delivering the most up-to-date, practice-changing data, VIVA brings together the latest science, technological innovation, and international expertise.
The VEINS (Venous Endovascular INterventional Strategies) complements this tradition with a dedicated focus on the diagnosis, intervention, and management of venous disorders, creating a comprehensive educational experience across the full vascular spectrum.
An international, multispecialty faculty will deliver live cases, interactive workshops, and expert discussions, alongside the presentation of groundbreaking clinical trial results, providing unmatched access to the latest advances in vascular care.
Media outlets are invited to attend in person or virtually. For press registration, contact [email protected].
The full agenda for both conferences is available at viva-foundation.org/agenda.
Clinical trial results to be presented:
Listed in presentation order*
The VEINS
Randomized Comparison of Cyanoacrylate Closure and Endothermal Ablation: Spectrum Secondary Outcomes Through 12 Months
Manj Gohel, MD
Clinical Feasibility and Safety Study of the Use of a Novel Device for the Treatment of Chronic Venous Insufficiency of the Lower Limb
Gastone Bergamaschi, MD
Impact of Junctional Reflux on the Effectiveness Of Endovenous Ablation In Patients With Great Saphenous Vein Insufficiency (JURY-2 Study)
Yana Etkin, MD
Short-Term Cost Effectiveness of Large Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis for Intermediate-Risk Pulmonary Embolism From the PEERLESS Randomized Controlled Trial
Samuel Horr, MD
Comparison of Real-World Outcomes in Pulmonary Embolism Patients Undergoing Large Bore Mechanical Thrombectomy or Receiving Anticoagulation Alone: Insights From the Premier Healthcare Database
Jay Giri, MD, MPH
Two-Year Clinical Outcomes From the Single-Arm Arteriovenous Graft Cohort of the WAVE Trial
Mahmood Razavi, MD
VIVA
Prolonged Efficacy and Safety of a Drug-Eluting Resorbable Scaffold in CLTI: Three-Year Outcomes and Subgroup Analyses From the LIFE-BTK Trial
Sahil A. Parikh, MD
One-Year Outcomes From the Disrupt PAD BTK II Study: Treatment of Patients With Calcified Below-the-Knee Lesions With a Peripheral Intravascular Lithotripsy System
Ehrin Armstrong, MD
Novel Thrombectomy System for Acute Intermediate-Risk Pulmonary Embolism: Full Results From the Pivotal ENGULF Trial
Andrew Klein, MD
STRIKE-PE: One-Year Functional Outcomes and Quality of Life in Pulmonary Embolism Patients Treated With Computer-Assisted Vacuum Thrombectomy Using the 16F Catheter System
John Moriarty, MD
Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk PE: Primary Outcome, Functional Endpoints, and Core Lab Findings From STORM-PE
Rachel Rosovsky, MD, MPH
Prospective, Multicenter Evaluation of Transcarotid Artery Revascularization (TCAR) In Standard-Risk Patients: 1-Year Outcomes of The ROADSTER 3 Study
Meghan Dermody, MD
Integrated Embolic Protection in TCAR: 30-Day Results From the PERFORMANCE III Trial
Sean P. Lyden, MD
Potential for Sustained Abdominal Aortic Aneurysm Growth Stabilization After a Single Intra-Aortic Administration of Pentagalloylglucose: Clinical Evidence From a Phase I Study With the Nectero EAST® System
Ramon L. Varcoe, MBBS
AGILITY: A Prospective, Multi-Center Evaluation of the BD Low Profile Vascular Covered Stent (Revello) in Peripheral Artery Disease
Sean P. Lyden, MD
Transcatheter Arterialization of the Deep Veins: Initial 6-Month Outcomes From the PROMISE III Trial
Dan Clair, MD
Peripheral Retrievable Stent Therapy: DEEPER REVEAL Clinical Trial 6-Month Outcomes
Mahmood Razavi, MD
MOTIV BTK RCT: Safety & Effectiveness Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold Compared with Plain Balloon Angioplasty for the Treatment of Infrapopliteal Lesions –Primary Safety Endpoint
Ehrin Armstrong, MD
One-Year Outcomes From the FORWARD PAD IDE and Feasibility Studies of the Treatment of Calcified PAD With a Novel Forward Peripheral Intravascular Lithotripsy System
Andrew Holden, MBChB
Additional Results From Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Peripheral Artery Disease (POWER PAD II)
D. Christopher Metzger, MD
Two-Year Clinical Outcomes From the Randomized-Controlled Arm of the WAVE Trial
David J. Dexter, MD
Wearable, Non-Invasive Therapeutic Ultrasound for Treatment of Critical Limb Threatening Ischemia: A Sham-Controlled Randomized Controlled Trial
Mahmood Razavi, MD
36-Month Performance of a Sirolimus-Eluting Balloon in Diabetic and Nondiabetic Patients With Femoropopliteal Artery Disease From the SELUTION SFA Japan Study
Yoshimitsu Soga, MD, PhD
*Order and presenters subject to change
About the VIVA Foundation
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, strives to be the premier educator in the field. Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field and improve patient outcomes. Educational events presented by the VIVA Foundation have a distinct spirit of collegiality attained by synergizing collective talents to promote awareness and innovative therapeutic options for vascular disease worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vascular-innovation-on-display-the-viva-foundation-set-to-unveil-latest-trial-data-at-the-veins-and-viva-2025-302553059.html
SOURCE The VIVA Foundation
